Oruka Therapeutics, Inc. (ORKA) Financial Statements
Oruka Therapeutics, Inc. (ORKA) reported trailing twelve-month revenue of $0 (up 0.0% year on year) and net income of -$132.9M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$101.2M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ORKAOruka Therapeutics, Inc.Follow ORKA — free
—
Price chart with a free account
- Market cap
- 5.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 18 Nov, in 25 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2006 Dec 06 | FY2007 Dec 07 | FY2008 Dec 08 | FY2009 Dec 09 | FY2010 Dec 10 | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.08 | 0.10 | 0.13 | |
| Operating income | — | — | — | — | — | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.09 | -0.12 | -0.16 | |
| Pre-tax income | — | — | — | — | — | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.08 | -0.11 | -0.13 | |
| Income tax | — | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | -0.00 | -0.00 | -0.00 | -0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |
| Net income | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | -0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.01 | -0.01 | -0.08 | -0.11 | -0.13 | |
| Diluted EPS ($) | — | — | — | — | — | -3.21 | -1.94 | -1.04 | -3.31 | -1.82 | -1.81 | -1.77 | -10.31 | -4.15 | -2.07 | -1.39 | -0.69 | -0.37 | — | — | — | |
| Diluted shares (bn) | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.014 | 0.014 | — | — | — |
USD billions · SEC XBRL
Oruka Therapeutics, Inc. — questions
- What is Oruka Therapeutics, Inc.'s revenue?
- $0 over the twelve months to 2026-06-30, up 0.0% year on year, from its 10-Q and 10-K filings.
- What is Oruka Therapeutics, Inc.'s net income?
- -$132.9M over the twelve months to 2026-06-30.
- What is Oruka Therapeutics, Inc.'s free cash flow?
- -$101.2M over the twelve months to 2026-06-30.
Every figure on this page comes from Oruka Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.